Rapid Development Through Clear Prioritization

In addition to our deep expertise in infectious diseases, we clearly define priorities and make focused investments to maximize outcomes with limited resources. By allocating development resources to priority areas, we drive development with speed—from clinical trials through regulatory submission. This capability for rapid development execution has been particularly demonstrated in the infectious diseases field.

While clinical development typically takes 3-7 years and an additional 1-2 years for regulatory filing and review, SHIONOGI achieved significantly faster timelines: Xocova reached launch in approximately 1 year and 6 months from the start of clinical trials, and Xofluza in 3 years and 1 month.